Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for matrix metalloproteinases, membrane- associated
Most Correlated Studies
- L1000 CMAP - Lung cancer A549 cells treated with ligand perturbagens
- L1000 CMAP - Adenocarcinoma of breast MCF7 cells treated with ligand perturbagens
- L1000 CMAP - Amelanotic malignant melanoma of skin A375 cells treated with ligand perturbagens
- L1000 CMAP - Colorectal cancer HT29 cells treated with ligand perturbagens
- L1000 CMAP - Prostate carcinoma VCaP cells treated with ligand perturbagens
Most Relevant Literature
- Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix me…
- Navigating ECM barriers at the invasive front: the cancer cell-stroma interface.
- Pore-forming bacterial toxins and antimicrobial peptides as modulators of ADAM function.
- Site-specific cellular functions of MT1-MMP.
- Membrane type-matrix metalloproteinases and tumor progression.
Most Relevant Clinical Trials
- Role of Extracellular Matrix in the Development of Airway Remodeling in Asthma
- Metalloproteinases and Recurrent Corneal Erosion Syndrome
- Role of A Disintegrin and Metalloproteinase (ADAM) in Epithelial Dysfunction
- A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With R…
- The Impact of Pregnancy and Pregnancy-associated Hypertension on Human Uterine Myometrial Artery Rea…
